Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059673 | 0.84 | MAP2K4 (0.62) | TTKMAP2K4FGFR1KDM4EALDH1A1 | |
| SCHEMBL4060826 | 0.84 | MAP2K4 (0.49) | TTKFGFR2FGFR3MAP2K4NTRK1 | |
| SCHEMBL4058556 | 0.82 | MAP2K4 (0.59) | TTKFGFR2FGFR3MAP2K4FGFR1 | |
| SCHEMBL4058171 | 0.81 | MAP2K4 (0.52) | FGFR2FGFR3MAP2K4FGFR1KDR | |
| SCHEMBL4061854 | 0.81 | MAP2K4 (0.48) | MAP2K4FGFR1ALDH1A1KDR | |
| SCHEMBL4056313 | 0.81 | MAP2K4 (0.48) | MAP2K4 | |
| SCHEMBL4061419 | 0.78 | PDPK1 (0.56) | FGFR2FGFR3MAP2K4FGFR1KDR | |
| SCHEMBL4065232 | 0.77 | MAP2K4 (0.48) | MAP2K4FGFR1ALDH1A1KDR | |
| SCHEMBL4059067 | 0.76 | MAP2K4 (0.50) | MAP2K4NTRK1FGFR1KDR | |
| SCHEMBL4063919 | 0.76 | MAP2K4 (0.50) | MAP2K4FGFR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | claimed |
| EP-1747202-A1 | INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-31 | — | — | EP | claimed |
| US-20050215595-A1 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-29 | — | — | US | claimed |
| WO-2005085206-A1 | INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | claimed |
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495015-B2 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20050215595-A1 | Indazole derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215595-A1 | Indazole derivatives and methods for using the same | MAPK1, MAP3K1, MAP3K7 | TTK 462/4885FGFR2 1576/4885FGFR3 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.